245.12
前日終値:
$244.76
開ける:
$245.15
24時間の取引高:
562.70K
Relative Volume:
0.54
時価総額:
$35.94B
収益:
$5.02B
当期純損益:
$1.31B
株価収益率:
27.51
EPS:
8.91
ネットキャッシュフロー:
$1.56B
1週間 パフォーマンス:
-0.15%
1か月 パフォーマンス:
+3.10%
6か月 パフォーマンス:
-1.57%
1年 パフォーマンス:
+19.01%
Resmed Inc Stock (RMD) Company Profile
RMD を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
RMD
Resmed Inc
|
245.12 | 36.00B | 5.02B | 1.31B | 1.56B | 8.91 |
![]()
ISRG
Intuitive Surgical Inc
|
555.75 | 194.50B | 8.71B | 2.48B | 1.75B | 6.82 |
![]()
BDX
Becton Dickinson Co
|
173.82 | 49.39B | 20.87B | 1.50B | 2.59B | 5.24 |
![]()
ALC
Alcon Inc
|
86.35 | 42.61B | 9.93B | 1.12B | 1.58B | 2.25 |
![]()
COO
The Cooper Companies, Inc.
|
79.96 | 15.86B | 3.93B | 415.40M | 384.70M | 2.06 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-03-19 | 開始されました | Morgan Stanley | Overweight |
2025-01-16 | 開始されました | Goldman | Buy |
2025-01-10 | 開始されました | Piper Sandler | Neutral |
2024-12-13 | 開始されました | Stifel | Hold |
2024-09-24 | 開始されました | Robert W. Baird | Outperform |
2024-09-18 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
2024-09-04 | ダウングレード | Needham | Buy → Hold |
2024-06-25 | ダウングレード | Oppenheimer | Outperform → Perform |
2024-06-24 | ダウングレード | Citigroup | Buy → Neutral |
2024-02-06 | 再開されました | KeyBanc Capital Markets | Overweight |
2023-10-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2023-10-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2023-10-09 | アップグレード | JP Morgan | Neutral → Overweight |
2023-09-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
2023-09-06 | アップグレード | Needham | Hold → Buy |
2023-09-05 | ダウングレード | UBS | Buy → Neutral |
2023-08-01 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2023-05-23 | 開始されました | UBS | Buy |
2023-04-14 | 開始されました | Mizuho | Buy |
2023-01-17 | アップグレード | JP Morgan | Neutral → Overweight |
2022-10-28 | ダウングレード | Citigroup | Buy → Neutral |
2022-10-20 | アップグレード | BofA Securities | Neutral → Buy |
2022-10-12 | 開始されました | Jefferies | Hold |
2022-09-08 | アップグレード | Citigroup | Neutral → Buy |
2022-08-15 | ダウングレード | CLSA | Buy → Outperform |
2022-08-12 | ダウングレード | Citigroup | Buy → Neutral |
2022-08-12 | ダウングレード | JP Morgan | Overweight → Neutral |
2022-08-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2022-06-06 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2022-04-06 | 開始されました | Wolfe Research | Outperform |
2022-01-31 | アップグレード | Citigroup | Neutral → Buy |
2022-01-31 | アップグレード | Goldman | Neutral → Buy |
2022-01-28 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
2022-01-24 | アップグレード | BofA Securities | Underperform → Neutral |
2022-01-24 | アップグレード | JP Morgan | Neutral → Overweight |
2022-01-13 | アップグレード | CLSA | Outperform → Buy |
2022-01-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
2021-12-21 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
2021-12-06 | アップグレード | Macquarie | Neutral → Outperform |
2021-10-22 | アップグレード | CLSA | Underperform → Outperform |
2021-08-02 | ダウングレード | CLSA | Outperform → Sell |
2021-08-02 | ダウングレード | Needham | Buy → Hold |
2021-07-28 | アップグレード | Jefferies | Underperform → Hold |
2021-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
2021-07-14 | 開始されました | RBC Capital Mkts | Underperform |
2021-06-28 | ダウングレード | Citigroup | Buy → Neutral |
2021-06-22 | アップグレード | Macquarie | Neutral → Outperform |
2021-06-22 | 開始されました | Robert W. Baird | Neutral |
2021-06-21 | 繰り返されました | Needham | Buy |
2021-06-16 | ダウングレード | BofA Securities | Neutral → Underperform |
2021-06-09 | アップグレード | CLSA | Sell → Outperform |
2021-05-21 | アップグレード | JP Morgan | Neutral → Overweight |
2021-05-11 | アップグレード | Citigroup | Neutral → Buy |
2021-04-30 | ダウングレード | Citigroup | Buy → Neutral |
2021-03-16 | アップグレード | Needham | Hold → Buy |
2020-11-02 | アップグレード | UBS | Neutral → Buy |
2020-10-30 | アップグレード | JP Morgan | Underweight → Neutral |
2020-10-27 | アップグレード | BofA Securities | Underperform → Neutral |
2020-08-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2020-06-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-05-01 | ダウングレード | JP Morgan | Neutral → Underweight |
2020-05-01 | アップグレード | Oppenheimer | Perform → Outperform |
2020-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2020-02-03 | 開始されました | CLSA | Underperform |
2020-01-31 | ダウングレード | UBS | Buy → Neutral |
2020-01-10 | 開始されました | Oppenheimer | Perform |
2019-11-22 | 開始されました | KeyBanc Capital Markets | Sector Weight |
2019-07-29 | アップグレード | UBS | Neutral → Buy |
2019-07-16 | ダウングレード | UBS | Buy → Neutral |
2019-05-06 | アップグレード | UBS | Neutral → Buy |
2019-04-18 | アップグレード | JP Morgan | Underweight → Neutral |
2019-01-25 | ダウングレード | Goldman | Buy → Neutral |
2019-01-25 | ダウングレード | JP Morgan | Neutral → Underweight |
2018-10-26 | アップグレード | Credit Suisse | Neutral → Outperform |
2018-07-02 | 開始されました | Goldman | Buy |
すべてを表示
Resmed Inc (RMD) 最新ニュース
ResMed Inc. Files Conflict Minerals Disclosure Report for 2024 - TipRanks
Actigraphy Devices Market Report 2025-2034 | Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape - GlobeNewswire Inc.
ResMed CFO Executes Stock Transaction Under Rule 10b5-1 Plan - TipRanks
ResMed CFO Brett Sandercock sells $891,285 in stock By Investing.com - Investing.com South Africa
Hedge Fund and Insider Trading News: Bill Ackman, Paul Tudor Jones, Chase Coleman, John Paulson, Polus Capital Management, VFC Corp (VFC), ResMed Inc (RMD), and More - Insider Monkey
ResMed CFO Brett Sandercock sells $891,285 in stock - Investing.com
ResMed’s SWOT analysis: sleep tech giant faces growth challenges, new markets - Investing.com
ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Are Wall Street Analysts Bullish on ResMed Stock? - Inkl
Are Wall Street Analysts Bullish On ResMed Stock? - Barchart.com
Is it Worth Retaining ResMed Stock in Your Portfolio Now? - Nasdaq
Insider Sell: Witte De Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus
ResMed CFO Sells Shares - marketscreener.com
Why Kogan, Monash IVF, OFX, and ResMed shares are falling today - MSN
Down 5%: What's going on with the ResMed share price? - MSN
RMD ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of ResMed Inc. Shareholders Who Lost Money - ACCESS Newswire
Morgan Stanley sees ‘modest’ earnings impact to ResMed from Apnimed - Yahoo Finance
Should you buy the dip in the ResMed share price? - MSN
ResMed Draws Analyst Skepticism After Apnimed Announces Positive Results From Investigational Sleep Apnea Drug: Retail’s Unmoved By Stocktwits - Investing.com India
ResMed Draws Analyst Skepticism After Apnimed Announces Positive Results From Investigational Sleep Apnea Drug: Retail’s Unmoved - MSN
Positive Phase 3 Trial Results for RMD's Sleep Apnea Treatment | - GuruFocus
ResMed (RMD) Faces Potential Market Challenges from New Sleep Ap - GuruFocus
ResMed (RMD) Faces Potential Market Challenges from New Sleep Apnea Treatment | RMD Stock News - GuruFocus
Here's Why ResMed (RMD) is a Strong Growth Stock - Yahoo Finance
ResMed (NYSE:RMD) Seems To Use Debt Rather Sparingly - simplywall.st
Apnea Therapy Market Is Booming Worldwide 2025-2032 | ResMed Inc., Koninklijke Philips N.V. - openPR.com
Resmed (RMD) Partners with Rugby Tour to Promote Sleep Health | - GuruFocus
ResMed named Sleep Partner of the Qatar Airways British & Irish Lions Tour - TipRanks
Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025 - The Spec
Patient Monitoring Stocks Q1 Teardown: ResMed (NYSE:RMD) Vs The Rest - Yahoo Finance
Resmed Inc Updates Dividend Exchange Rate for CDI Holders - TipRanks
Levi & Korsinsky Reminds ResMed Investors of the Ongoing Investigation into Potential Violations of Securities LawsRMD - ACCESS Newswire
ResMed CEO Michael Farrell sells $1.95m in stock By Investing.com - Investing.com Canada
Resmed Insider Sold Shares Worth $1,948,003, According to a Recent SEC Filing - marketscreener.com
ResMed CEO Michael Farrell sells $1.95m in stock - Investing.com
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus
Resmed prevails over Cleveland Medical in CPAP patent review - BioWorld MedTech
Is ResMed Inc.'s (NYSE:RMD) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st
Ex-Dividend Reminder: Seaboard, KB Home and ResMed - Nasdaq
ResMed Inc Reports Changes in CDIs and Securities for April 2025 - TipRanks
Jim Cramer on Viemed Healthcare (VMD): “Interesting, But I’m a ResMed Guy” - Yahoo Finance
ResMed Wins Invalidation of Sleep Apnea Tech Patent After Remand - Bloomberg Law News
Is It Smart To Buy ResMed Inc. (NYSE:RMD) Before It Goes Ex-Dividend? - Yahoo Finance
ResMed Corporation: GLP-1 Demand Generation Strategy to Expand Customer Base & Strengthen Their Position! - Smartkarma
Intuitive wins new FDA nod for single port robot; Resmed buys diagnostic facility - MedTech Dive
This ResMed Insider Reduced Their Stake By 72% - Yahoo Finance
Resmed acquires independent diagnostic testing facility VirtuOx - Yahoo Finance
Resmed Inc (RMD) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):